Who Paid My Doc
Research studies in the Open Payments record
139,921 studies have research funding reported against them. Being named on a study as a principal investigator is reported separately from being paid.
Studies
50 of 139,921- 2017 Aspire Oncology Hematology A Phase 1 Study of Palbociclib A CDK 4 6 Inhibitor in Combination With Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia All Or Lymphoblastic Lymphoma LL No ClinicalTrials.gov identifier reported
- 2017 Aspire Oncology Hematology A Phase 1 Study of Palbociclib A CDK 4 6 Inhibitor in Combination With Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia All Or Lymphoblastic Lymphoma LL No ClinicalTrials.gov identifier reported
- 2017 Aspire Oncology Hematology A Phase 1 Study of Palbociclib Letrozole and Tdm1 in Trastuzumab Refractory Estrogen Receptor Positive and Her2 Positive Metastatic Breast Cancer No ClinicalTrials.gov identifier reported
- 2017 Aspire Oncology Hematology A Phase I Trial of Palbociclib and Bosutinib With Fulvestrant in Patients With Metastatic Hormone Receptor Positive and Her2 Negative Breast Cancer Refractory to An Aromatase Inhibitor and A Cdk4 6 Inhibitor No ClinicalTrials.gov identifier reported
- 2017 Aspire Oncology Hematology A Phase I Trial of Palbociclib and Bosutinib With Fulvestrant in Patients With Metastatic Hormone Receptor Positive and Her2 Negative Breast Cancer Refractory to An Aromatase Inhibitor and A Cdk4 6 Inhibitor No ClinicalTrials.gov identifier reported
- 2017 Aspire Oncology Hematology Immune Modulation in Early Stage Estrogen Receptor Positive Breast Cancer Treated With Neoadjuvant Avelumab Palbociclib and Tamoxifen the Immunoadapt Study No ClinicalTrials.gov identifier reported
- 2017 Aspire Oncology Hematology Immune Modulation in Early Stage Estrogen Receptor Positive Breast Cancer Treated With Neoadjuvant Avelumab Palbociclib and Tamoxifen the Immunoadapt Study No ClinicalTrials.gov identifier reported
- 2017 Aspire Oncology Hematology Incidence Course and Predictors of Fatigue Developing on Palbociclib in Advanced HR Positive Her2 Negative Breast Cancer No ClinicalTrials.gov identifier reported
- 2017 Aspire US Rheuma Ibd A Cellular Biomarker to Distinguish Axial Spondyloarthritis From Mechanical Back Pain No ClinicalTrials.gov identifier reported
- 2017 Aspire US Rheuma Ibd Electrocardiographic Abnormalities in Systemic Lupus Erythematosus No ClinicalTrials.gov identifier reported
- 2017 Aspire US Rheuma Ibd Microbial Basis of Fatigue in Inflammatory Bowel Diseases Towards Microbiomedirected Therapeutics No ClinicalTrials.gov identifier reported
- 2017 Aspire US Rheuma Ibd Rheumatoid Arthritisrelated Autoantibodies in Sputum As A Prognostic Indicator of Interstitial Lung Disease No ClinicalTrials.gov identifier reported
- 2017-Fc-045 No ClinicalTrials.gov identifier reported
- 2017-NIV-0753 Nivolumab plus Cisplatin and Pemetrexed or Cisplatin and Gemcitabine as Induction in Resectable NSCLC No ClinicalTrials.gov identifier reported
- 2017-NIV-0758 Open-label, single arm ph2 stdy to evaluate Biomarkers of response to ipilimumab and nivolumab as 1st-line therapy for metastatic NSCLC No ClinicalTrials.gov identifier reported
- 2017-NIV-0786 A ph 2 Open-label Study of Nivo Combined with Cabozantinib in Subjects w Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma No ClinicalTrials.gov identifier reported
- 2017-NIV-0789 A Ph I open label trial of a combo of nivolumab and bevacizumab in patients with advanced and or metastatic hepatocellular carcinoma No ClinicalTrials.gov identifier reported
- 2017-NIV-0802 A Ph I safety study incorp nivo to definitive chemoradiation for women with newly diagnosed cervical cancer (stages I-IVA) No ClinicalTrials.gov identifier reported
- 2017-NIV-0802 A Ph I safety study incorp nivo to definitive chemoradiation for women with newly diagnosed cervical cancer stages I-IVA No ClinicalTrials.gov identifier reported
- 2017-NIV-0807 A Randomized Ph II trial of Nivolumab plus Ramucirumab in Patients with Recurrent, Advanced, Metastatic NSCLC No ClinicalTrials.gov identifier reported
- 2017-NIV-0832 Safety Lead-in to asses the antitumorefficacy of combo ido- inhibitor and nivo in patients with recurrent or persistent endometrial cancer No ClinicalTrials.gov identifier reported
- 2017-NIV-0835 Dual Checkpoint Blockade and Neoadjuvant Radiotherapy in Soft Tissue Sarcoma No ClinicalTrials.gov identifier reported
- 2017-NIV-0838 Nivolumab in Conjunction with the Dendritic Cell Multiple Myeloma Fusion Vaccine as a Means to Induce Myeloma-specific Immunity No ClinicalTrials.gov identifier reported
- 2017-NIV-0855 The combination of radioembolization w/ Nivolumab in Pts w/ unresectable advanced HCC No ClinicalTrials.gov identifier reported
- 2017-ORE-0088 The effect of abatacept on osteoclastogenesis and its potential therapeutic use in children with chronic nonbacterial osteomyelitis No ClinicalTrials.gov identifier reported
- 2017-ORE-0093 Abatacept and Cyclophosphamide for GVHD prophylaxis No ClinicalTrials.gov identifier reported
- 2018-0701 No ClinicalTrials.gov identifier reported
- 2018-071 No ClinicalTrials.gov identifier reported
- 2018-072 No ClinicalTrials.gov identifier reported
- 2018-073 No ClinicalTrials.gov identifier reported
- 2018-074 No ClinicalTrials.gov identifier reported
- 201808057 No ClinicalTrials.gov identifier reported
- 201809111 No ClinicalTrials.gov identifier reported
- 2018-3440 Suhocki No ClinicalTrials.gov identifier reported
- 2018-3440-Suhocki No ClinicalTrials.gov identifier reported
- 2018-3440- Suhocki No ClinicalTrials.gov identifier reported
- 2018-3442 Goldman No ClinicalTrials.gov identifier reported
- 2018-3552 Lim No ClinicalTrials.gov identifier reported
- 2018-3552-Lim No ClinicalTrials.gov identifier reported
- 2018-3619-Chey No ClinicalTrials.gov identifier reported
- 2018-3620 Kerdel No ClinicalTrials.gov identifier reported
- 2018-3706 Chamie No ClinicalTrials.gov identifier reported
- 2018-3707 Chamie No ClinicalTrials.gov identifier reported
- 2018-3818-Lacy No ClinicalTrials.gov identifier reported
- 2018-3818- Lacy No ClinicalTrials.gov identifier reported
- 2018-4225 Biesman No ClinicalTrials.gov identifier reported
- 2018-4225-Biesman No ClinicalTrials.gov identifier reported
- 2018-4257 - Wanner No ClinicalTrials.gov identifier reported
- 2018-4904 Krueger No ClinicalTrials.gov identifier reported
- 2018-4904-Krueger No ClinicalTrials.gov identifier reported